Hikma Pharmaceuticals PLC (LON:HIK)
1,785.00
-30.00 (-1.65%)
Aug 29, 2025, 4:35 PM BST
Hikma Pharmaceuticals Employees
Hikma Pharmaceuticals had 9,500 employees as of December 31, 2024. The number of employees increased by 400 or 4.40% compared to the previous year.
Employees
9,500
Change (1Y)
400
Growth (1Y)
4.40%
Revenue / Employee
247.09K GBP
Profits / Employee
28.50K GBP
Market Cap
4.02B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 9,500 | 400 | 4.40% |
Dec 31, 2023 | 9,100 | 300 | 3.41% |
Dec 31, 2022 | 8,800 | 100 | 1.15% |
Dec 31, 2021 | 8,700 | 100 | 1.16% |
Dec 31, 2020 | 8,600 | 0 | - |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Company Name | Employees |
---|---|
AstraZeneca | 94,300 |
GSK plc | 68,629 |
Haleon | 24,561 |
Smith & Nephew | 17,349 |
ConvaTec Group | 10,489 |
HUTCHMED (China) | 1,811 |
Oxford Nanopore Technologies | 1,382 |
Genus | 3,500 |
Hikma Pharmaceuticals News
- 20 days ago - Hikma Pharmaceuticals PLC (HKMPF) Q2 2025 Pre Recorded Earnings Call Transcript - Seeking Alpha
- 21 days ago - Hikma Pharmaceuticals PLC 2025 Q2 - Results - Earnings Call Presentation - Seeking Alpha
- 21 days ago - Hikma Pharmaceuticals PLC (HKMPF) Q2 2025 Q&A Earnings Call Transcript - Seeking Alpha
- 22 days ago - Hikma Pharmaceuticals tumbles after injectables margin outlook cut - Reuters
- 5 weeks ago - Hikma Pharmaceuticals: a quality compounder waiting for a catalyst - The Armchair Trader
- 2 months ago - Hikma receives FDA approval for TYZAVAN™ (Vancomycin Injection, USP) in the US - PRNewsWire
- 2 months ago - Hikma Pharmaceuticals to invest $1B by 2030 to expand US manufacturing, R&D - Seeking Alpha
- 2 months ago - Hikma Pharmaceuticals USA announces $1 Billion of new US investment to further expand its domestic manufacturing and development of essential generic medicines - PRNewsWire